Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CDC42 | P60953 | 1/20 | 0.46 |
| ▸ | RAC1 | P63000 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8069881 | 0.86 | LMNA (0.50) | MAPK1ALDH1A1CYP3A4MAPTPOLB | |
| SCHEMBL28803341 | 0.83 | MAPT (0.49) | MAPK1ALDH1A1CYP3A4MAPTNPC1 | |
| SCHEMBL17295989 | 0.83 | LDHA (0.52) | ALDH1A1MAPTNPC1RAB9APOLB | |
| SCHEMBL3829660 | 0.83 | LDHA (0.52) | ALDH1A1MAPTNPC1RAB9APOLB | |
| SCHEMBL17295985 | 0.83 | LDHA (0.52) | ALDH1A1MAPTNPC1RAB9APOLB | |
| SCHEMBL31359577 | 0.83 | MAPT (0.64) | MAPK1ALDH1A1CYP3A4MAPTNPC1 | |
| SCHEMBL9768743 | 0.81 | MEN1 (0.50) | ALDH1A1MAPTNPC1RAB9APOLB | |
| SCHEMBL8069856 | 0.81 | ALDH1A1 (0.51) | MAPK1ALDH1A1CYP3A4RAB9APOLB | |
| SCHEMBL8068274 | 0.81 | CYP3A4 (0.51) | ALDH1A1CYP3A4MAPTMEN1KMT2A | |
| SCHEMBL8475294 | 0.81 | KLK7 (0.48) | ALDH1A1MAPTNPC1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660504-B1 | THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1660504-B1 | THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER (US) | 2008-10-29 | — | — | EP | disclosed |
| US-7208500-B2 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | AGOURON PHARMACEUTICALS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208500-B2 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | AGOURON PHARMACEUTICALS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208500-B2 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | AGOURON PHARMACEUTICALS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1660504-A1 | THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050090509-A1 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | Agouron Pharmaceuticals,Inc. | 2005-04-28 | — | — | US | disclosed |
| WO-2005021554-A1 | THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090509-A1 | Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents | CCNA1, PGF, CCNA2 | MAPK1 843/4885ALDH1A1 537/4885CYP3A4 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.